Glen Harbor Capital Management LLC increased its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 6.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 21,582 shares of the medical instruments supplier’s stock after buying an additional 1,342 shares during the period. Glen Harbor Capital Management LLC’s holdings in Becton Dickinson and were worth $5,170,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of BDX. HC Financial Advisors Inc. acquired a new position in Becton Dickinson and during the 4th quarter worth about $2,456,000. Alps Advisors Inc. acquired a new position in Becton Dickinson and during the 1st quarter worth about $209,000. Commerce Bank lifted its position in Becton Dickinson and by 10.8% during the 1st quarter. Commerce Bank now owns 153,686 shares of the medical instruments supplier’s stock worth $33,304,000 after buying an additional 14,984 shares in the last quarter. Middleton & Co Inc MA lifted its position in Becton Dickinson and by 18.0% during the 1st quarter. Middleton & Co Inc MA now owns 2,172 shares of the medical instruments supplier’s stock worth $471,000 after buying an additional 331 shares in the last quarter. Finally, Bbva Compass Bancshares Inc. lifted its position in Becton Dickinson and by 10.1% during the 1st quarter. Bbva Compass Bancshares Inc. now owns 12,382 shares of the medical instruments supplier’s stock worth $2,683,000 after buying an additional 1,137 shares in the last quarter. Institutional investors and hedge funds own 86.73% of the company’s stock.

Shares of NYSE:BDX opened at $254.37 on Friday. The stock has a market cap of $68.41 billion, a price-to-earnings ratio of 26.83, a PEG ratio of 1.74 and a beta of 1.10. Becton Dickinson and Co has a 1-year low of $191.53 and a 1-year high of $263.37. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.86 by $0.05. The firm had revenue of $4.28 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.46 EPS. sell-side analysts expect that Becton Dickinson and Co will post 11.01 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be issued a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, September 6th. This represents a $3.00 annualized dividend and a yield of 1.18%. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

Several research analysts recently issued reports on BDX shares. KeyCorp reiterated a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Royal Bank of Canada reiterated a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday, May 29th. Citigroup boosted their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective for the company in a report on Thursday, June 21st. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and an average target price of $251.64.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: What is a Tariff?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.